Ann Marie Mauer to Carboplatin
This is a "connection" page, showing publications Ann Marie Mauer has written about Carboplatin.
Connection Strength
0.263
-
Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancer. J Thorac Oncol. 2008 Jan; 3(1):59-67.
Score: 0.073
-
A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer. Clin Cancer Res. 2007 Jan 15; 13(2 Pt 1):515-22.
Score: 0.068
-
Phase I/II investigation of paclitaxel, ifosfamide and carboplatin for advanced non-small-cell lung cancer. Ann Oncol. 2003 May; 14(5):722-8.
Score: 0.053
-
Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer. J Thorac Oncol. 2008 Sep; 3(9):1003-11.
Score: 0.019
-
Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203. J Clin Oncol. 2008 Feb 20; 26(6):848-55.
Score: 0.018
-
Carboplatin plus vinorelbine with concomitant radiation therapy in advanced non-small cell lung cancer: a phase I study. Lung Cancer. 2002 Oct; 38(1):65-71.
Score: 0.013
-
Ifosfamide-based three-drug combination regimens in non-small cell lung cancer. Semin Oncol. 1998 Feb; 25(1 Suppl 2):19-22.
Score: 0.009
-
Paclitaxel/carboplatin plus ifosfamide in non-small cell lung cancer. Semin Oncol. 1997 Aug; 24(4 Suppl 12):S12-67-S12-69.
Score: 0.009